Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2024 value amounting to $235.4 million.

  • KalVista Pharmaceuticals' Liabilities and Shareholders Equity was N/A to $294.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $891.2 million, marking a year-over-year change of. This contributed to the annual value of $235.4 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, KalVista Pharmaceuticals' Liabilities and Shareholders Equity is $235.4 million, which was up 154.41% from $92.5 million recorded in FY2020.
  • KalVista Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $235.4 million for FY2024, and its period low was $92.5 million during FY2020.
  • In the last 1 years, KalVista Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $235.4 million in 2024 and averaged $235.4 million.
  • Data for KalVista Pharmaceuticals' Liabilities and Shareholders Equity shows a maximum YoY dropped of 21.67% (in 2020) over the last 5 years.
  • Over the past 2 years, KalVista Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $92.5 million in 2020, then followed by $235.4 million in 2024.